PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53

References

• Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, et al. Diagnosis and Management of Waldenstr?m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clin Proc 2010; 85:824-833; PMID:20702770; http://dx.doi.org/10.4065/mcp.2010.0304.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:503-510; PMID:22508368; http://dx.doi.org/10.1002/ajh.23192.
   PubMed Web of Science ®Google Scholar
• Shaheen SP, Talwalkar SS, Lin P, Medeiros LJ. Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. Adv Anat Pathol 2012; 19:11-27; PMID:22156831; http://dx.doi.org/10.1097/PAP.0b013e31824019d0.
   PubMed Web of Science ®Google Scholar
• Gertz M. Waldenström macroglobulinemia: my way. Leuk. Lymphoma 2013; 54:464-471; http://dx.doi.org/10.3109/10428194.2012.717173.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-431; PMID:19410540; http://dx.doi.org/10.1016/j.cell.2009.04.037.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458:1127-1130; PMID:19407794; http://dx.doi.org/10.1038/nature07986.
   PubMed Web of Science ®Google Scholar
• Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8:25-37; PMID:20975744; http://dx.doi.org/10.1038/nrclinonc.2010.174.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-288; PMID:11875500; http://dx.doi.org/10.1038/nm0302-282.
   PubMed Web of Science ®Google Scholar
• Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 2011; 17:2830-2841; PMID:21415220; http://dx.doi.org/10.1158/1078-0432.CCR-10-3168.
   PubMed Web of Science ®Google Scholar
• Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Strömblad S. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 2011; 10:301-307; PMID:21239882; http://dx.doi.org/10.4161/cc.10.2.14538.
   PubMed Web of Science ®Google Scholar
• Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009; 35:1015-1023; PMID:19787255.
   PubMed Web of Science ®Google Scholar
• Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008; 141:445-453; PMID:18341636; http://dx.doi.org/10.1111/j.1365-2141.2008.07046.x.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30:3633-3639; PMID:22965953; http://dx.doi.org/10.1200/JCO.2011.40.7783.
   PubMed Web of Science ®Google Scholar
• Lambert JMR, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJN. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15:376-388; PMID:19411067; http://dx.doi.org/10.1016/j.ccr.2009.03.003.
   PubMed Web of Science ®Google Scholar
• Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004; 127:285-291; PMID:15491287; http://dx.doi.org/10.1111/j.1365-2141.2004.05210.x.
   PubMed Web of Science ®Google Scholar
• Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008; 86:407-411; PMID:18237796; http://dx.doi.org/10.1016/j.radonc.2008.01.001.
   PubMed Web of Science ®Google Scholar
• Ali D, Jönsson-Videsäter K, Deneberg S, Bengtzén S, Nahi H, Paul C, Lehmann S. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol 2011; 86:206-215; PMID:21114538; http://dx.doi.org/10.1111/j.1600-0609.2010.01557.x.
   PubMed Web of Science ®Google Scholar
• Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013; 12:2331-2341; PMID:24030633; http://dx.doi.org/10.1158/1535-7163.MCT-12-1166.
   PubMed Web of Science ®Google Scholar
• Lambert JMR, Moshfegh A, Hainaut P, Wiman KG, Bykov VJN. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010; 29:1329ne (20; http://dx.doi.org/10.1038/onc.2009.425.
   Web of Science ®Google Scholar
• Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113 (Pt 10):16610) 10).
   Google Scholar
• Agarwal A, Ghobrial IM. The bone marrow microenvironment in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13, 218-221; PMID:23490994; http://dx.doi.org/10.1016/j.clml.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianì F, Vigneri R, Frasca F. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer 2012; 130:2259-2270; PMID:21647879; http://dx.doi.org/10.1002/ijc.26228.
   PubMed Web of Science ®Google Scholar
• Aryee DNT, Niedan S, Ban J, Schwentner R, Muehlbacher K, Kauer M, Kofler R, Kovar H. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. Br J Cancer 2013; 109:2696-2704; PMID:24129240; http://dx.doi.org/10.1038/bjc.2013.635.
   PubMed Web of Science ®Google Scholar
• Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenström's macroglobulinemia. Haematologica 2012; 97:1281-1290; PMID:22773606; http://dx.doi.org/10.3324/haematol.2012.068478.
   PubMed Web of Science ®Google Scholar
• Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006; 132:230-236; PMID:16398657.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Descamps G, Moreau P, MaG S, Lod L, Godon C, Marionneau-Lambot S, Oullier T, Le Gouill S, Amiot M, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 2014; 124:1626 et al; http://dx.doi.org/10.1182/blood-2014-01-548800.
   PubMed Web of Science ®Google Scholar
• Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011; 12:471-480; PMID:22204764.
   PubMed Web of Science ®Google Scholar
• Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9:6-19; PMID:11803370; http://dx.doi.org/10.1038/sj.cdd.4400969.
   PubMed Web of Science ®Google Scholar
• Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MAZ, et al. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007; 35:1366-1375; PMID:17761288.
   PubMed Web of Science ®Google Scholar
• Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, et al. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL−1. Blood 2011; 117:e190-197; PMID:21415268; http://dx.doi.org/10.1182/blood-2010-12-326868.
   PubMedGoogle Scholar
• Trudel S, Stewart AK, Li Z, Shu Y, Liang S-B, Trieu Y, Reece D, Paterson J, Wang D, Wen X-Y. The Bcl−2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13:621-629; PMID:17255285.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681; PMID:16968952; http://dx.doi.org/10.1124/pr.58.3.10.
   PubMed Web of Science ®Google Scholar